尽管科学家们在HFrEF的治疗研究上取得了重大进展，但HFrEF所产生的并发症和死亡率仍然很高，此外，大多数已经展现出对HFrEF患者有益的药物在HFpEF患者中并未表现出类似的治疗效益，这或许就突出了开发针对这两种心力衰竭亚型的靶向性疗法的迫切需要。

Infection-related hospitalization (IRH) is associated with incident heart failure, heart failure with preserved ejecti ...

Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Research Triangle Park, North Carolina Saturday, February 15, 2025, 17:00 Hrs [IST] ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

Heart failure is classified into two major clinical subtypes— heart failure with preserved ejection fraction (HFpEF) and ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...